**Nigeria**  
**Support for Yellow Fever Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Nigeria
2. **Grant number:** 1319-NGA-06q-X / 1921-NGA-21a-Y
3. **Date of Decision Letter:** 21 March 2019
4. **Date of the Partnership Framework Agreement:** 9 January 2014
5. **Programme title:** NVS, Yellow Fever Campaign
6. **Vaccine type:** Yellow Fever
7. **Requested product presentation and formulation of vaccine:** Yellow Fever, 10 dose(s) per vial, LYOPHILISED
8. **Programme duration:** 2019 -2021
9. **Programme Budget (indicative):** (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Total 2</th>
</tr>
</thead>
</table>
10. **Vaccine introduction grant (in US$):** Not applicable
11. **Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable):

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Yellow Fever vaccines doses</td>
<td>23,134,400</td>
<td>29,964,200</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$28,254,500</td>
<td>US$36,895,500</td>
</tr>
</tbody>
</table>

12. **Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
13. **Self-procurement:** Not applicable
14. **Co-financing obligations:** Not applicable

---

1 This is the entire duration of the Programme.
2 This is the total amount endorsed by Gavi for the entire duration of the Programme.
3 This is the amount that Gavi has approved.
15. **Operational support for campaigns:** The support for operational costs for the campaign will be disbursed in cash through WHO and UNICEF. The Country will need to contact the local WHO and UNICEF office to arrange the utilisation of GAVI funds to support the operational costs of the campaign.

<table>
<thead>
<tr>
<th>Grant Amount (US$)</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>US$8,446,991</td>
<td>US$10,940,761</td>
<td></td>
</tr>
</tbody>
</table>

16. **Additional reporting requirements:** Not applicable

<table>
<thead>
<tr>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 March 2019</td>
</tr>
<tr>
<td>15 May 2019</td>
</tr>
</tbody>
</table>

To prepare for the annual procurement of vaccines, Country shall submit the following information each year:
- vaccine stock levels including buffer stock, by end of March;
- number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

Post campaign coverage survey report

Country shall deliver a campaign technical and financial report the latest 3 months after the campaign is over

3 Months after end of campaign

17. **Financial clarifications:** Not applicable

18. **Other conditions:** There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

Signed by,

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
21 March 2019

Global Health Campus, Ch. du Pommier 40
1218 Grand-Saconnex, Geneva, Switzerland
Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50
www.gavi.org info@gavi.org